Published in Fam Cancer on June 01, 2010
Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues. BMC Med Ethics (2011) 1.08
Consumer awareness and attitudes about insurance discrimination post enactment of the Genetic Information Nondiscrimination Act. Fam Cancer (2012) 0.99
Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia. Genet Med (2011) 0.96
Public awareness of genetic nondiscrimination laws in four states and perceived importance of life insurance protections. J Genet Couns (2014) 0.84
Genetics and Personal Insurance: the Perspectives of Canadian Cancer Genetic Counselors. J Genet Couns (2015) 0.77
"Would you test your children without their consent?" and other sticky dilemmas in the field of cancer genetic testing. Fam Cancer (2014) 0.75
Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. Front Genet (2017) 0.75
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol (2009) 4.84
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA (2007) 2.91
Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med (2008) 2.53
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol (2012) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol (2009) 1.30
Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev (2007) 1.25
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
If we build it ... will they come?--establishing a cancer genetics services clinic for an underserved predominantly Latina cohort. J Genet Couns (2006) 1.15
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS One (2011) 1.12
Social-cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer. Psychooncology (2008) 1.11
Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med (2007) 1.09
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat (2012) 1.09
Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw (2010) 1.05
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res (2011) 1.05
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. Patient Educ Couns (2011) 1.03
Colorectal cancer surveillance behaviors among members of typical and attenuated FAP families. Am J Gastroenterol (2007) 1.03
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res (2009) 1.01
Clinical germline genetic testing for melanoma. Lancet Oncol (2004) 1.00
Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther (2012) 1.00
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer (2014) 0.97
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2006) 0.97
Women's perceptions of the personal and family impact of genetic cancer risk assessment: focus group findings. J Genet Couns (2009) 0.97
Personalized cancer genetics training for personalized medicine: improving community-based healthcare through a genetically literate workforce. Genet Med (2011) 0.95
Beliefs and interest in cancer risk in an underserved Latino cohort. Prev Med (2006) 0.94
Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genet Med (2005) 0.93
Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat (2009) 0.92
BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol (2011) 0.91
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst (2015) 0.90
Comparison of Latina and non-Latina white women's beliefs about communicating genetic cancer risk to relatives. J Health Commun (2008) 0.90
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Res (2013) 0.90
Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet (2012) 0.90
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2014) 0.89
Variants of uncertain significance in breast cancer-related genes: real-world implications for a clinical conundrum. Part one: clinical genetics recommendations. Semin Oncol (2011) 0.88
Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat (2011) 0.88
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet (2011) 0.87
Creating tomorrow's leaders in cancer prevention: a novel interdisciplinary career development program in cancer genetics research. J Cancer Educ (2006) 0.87
Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. Fam Cancer (2010) 0.86
Future directions for postdoctoral training in cancer prevention: insights from a panel of experts. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions. Mol Diagn Ther (2013) 0.85
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev (2011) 0.84
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet (2012) 0.84
Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Ann Surg Oncol (2015) 0.83
Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. Fam Cancer (2008) 0.83
Health beliefs of women with and without breast cancer seeking genetic cancer risk assessment. Cancer Nurs (2005) 0.83
Assessing breast cancer risk and BRCA1/2 carrier probability. Breast Dis (2007) 0.83
Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns (2011) 0.82
Closing the loop: action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs. J Cancer Educ (2012) 0.81
Genetic cancer risk assessment in the newly diagnosed breast cancer patient is useful and possible in practice. J Clin Oncol (2005) 0.81
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2014) 0.81
Development of a cancer genetics education program for clinicians. J Cancer Educ (2002) 0.81
Impact of web-based case conferencing on cancer genetics training outcomes for community-based clinicians. J Cancer Educ (2012) 0.80
Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals. Fam Cancer (2009) 0.80
Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. Ann Surg Oncol (2008) 0.80
Screening-detected breast cancer in a man with BRCA2 mutation: case report. Radiology (2004) 0.80
Assessing the predictive accuracy of hMLH1 and hMSH2 mutation probability models. J Genet Couns (2006) 0.78
Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers. Oncol Nurs Forum (2006) 0.78
Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Brief Bioinform (2015) 0.78
Microsatellite instability is a rare finding in tumors of patients with both primary renal and rectal neoplasms. Cancer Genet Cytogenet (2004) 0.78
BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer (2008) 0.76
Linkage of a pedigree drawing program and database to a program for determining BRCA mutation carrier probability. Fam Cancer (2005) 0.76
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst (2017) 0.75
Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners. J Am Acad Nurse Pract (2008) 0.75
Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGE) in the analysis of BRCA1 exon 11 mutations in a high-risk breast cancer cohort. Hum Mutat (2002) 0.75
Breast cancer and the family tree. An issue for all practice settings. Adv Nurse Pract (2007) 0.75